Selective Optimization of Side Activities: Another Way for Drug Discovery
- 13 February 2004
- journal article
- review article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (6) , 1303-1314
- https://doi.org/10.1021/jm030480f
Abstract
No abstract availableThis publication has 40 references indexed in Scilit:
- IKs channel blockers: Potential antiarrhythmic agentsDrugs of the Future, 2001
- Inhibition of respiratory syncytial virus by a new class of chemotherapeutic agentsDrugs of the Future, 2000
- Search for new lead compounds: The example of the chemical and pharmacological dissection of aminopyridazinesJournal of Heterocyclic Chemistry, 1998
- A Method for Visualizing Recurrent Topological Substructures in Sets of Active MoleculesJournal of Chemical Information and Computer Sciences, 1998
- YM-50001NeuroReport, 1996
- Dexniguldipine-HCl is a potent allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cellsEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- Radioautographic Evidence that the GABAAReceptor Antagonist SR 95531 is a Substrate Inhibitor of MAO-A in the Rat and Human Locus CoeruleusEuropean Journal of Neuroscience, 1994
- (+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of α1-adrenoceptorsEuropean Journal of Pharmacology: Molecular Pharmacology, 1989
- 2-Aryloxymethyl-2,3,5,6-tetrahydro-1,4-oxazines, a new class of antidepressantsJournal of Medicinal Chemistry, 1975
- New class of sympathetic .beta.-receptor blocking agents. 3,4-Dihydro-3-hydroxy-1,5-benzoxazocinesJournal of Medicinal Chemistry, 1970